Nemolizumab for treating prurigo nodularis [ID6451]

  • In development
  • GID-TA11566
  • Expected publication date: TBC

NICE has paused the evaluation of nemolizumab for treating prurigo nodularis [ID6451] because the company and NHSE have commenced commercial discussions

Please note ID6451 indication is now a separate appraisal from ID6221 indication. The appraisal will be running on the same timelines as ID6221. Please see relevant topic webpages for further information.